



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/081,618	02/21/2002	Heinrich Gers-Barlag	Beiers 586.2-HCL	2616
7590	11/14/2003		EXAMINER	
			HARTLEY, MICHAEL G	
			ART UNIT	PAPER NUMBER
			1616	4
DATE MAILED: 11/14/2003				

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)
	10/081,618	GERS-BARLAG ET AL.
	Examiner Michael G. Hartley	Art Unit 1616

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM
 THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on ____.
- 2a) This action is **FINAL**. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 13-24 is/are pending in the application.
 - 4a) Of the above claim(s) ____ is/are withdrawn from consideration.
- 5) Claim(s) ____ is/are allowed.
- 6) Claim(s) 13-24 is/are rejected.
- 7) Claim(s) ____ is/are objected to.
- 8) Claim(s) ____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on ____ is/are: a) accepted or b) objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. §§ 119 and 120

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. 09/389,684.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.
- 13) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application) since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.
 - a) The translation of the foreign language provisional application has been received.
- 14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121 since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.

Attachment(s)

1) <input type="checkbox"/> Notice of References Cited (PTO-892)	4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s). ____ .
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)
3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s) ____ .	6) <input type="checkbox"/> Other: _____

Art Unit: 1616

Response to Amendment

The preliminary amendment filed 2/21/2002 has been entered. Claims 1-12 have been canceled.

New claims 13-24 have been added.

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 13-18, 21 and 22 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-12 of U.S. Patent No. 6,379,680. Although the conflicting claims are not identical, they are not patentably distinct from each other because claim 13 is generic to all that is recited in claim 1 of the patent. That is, claim 13 falls entirely within the scope of claim 1 of the patent, or in other words, claim 13 is anticipated by claim 1 of the patent. Claim 1 of the patent limits the coating on the surface of the metal oxide, while claim 13 is generic to the particles but has the same properties as afforded thereby (and such coatings are in dependent claims). For example, the pigment particles defined by claim 1 of the patent are within the scope of the generic claimed pigment particles claimed. The pending claims also recite "Pickering emulsions" in the preamble; however, the specification of the patent defines the emulsions to be Pickering emulsions. Also, since the same components may be present in the claimed and patented emulsions, the term "Pickering" in the preamble of the patent claims does not differentiate. Another difference is the claims require at least one polymeric moisturizer, while the patented claims are generic thereto, by optionally having auxiliaries, additives and/or active ingredients, which are defined by the specification to encompass such moisturizers.

Art Unit: 1616

Claims 13-18, 21 and 22 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-8 of U.S. Patent No. 6,582,707. Although the conflicting claims are not identical, they are not patentably distinct from each other because claim 13 is generic to all that is recited in claim 1 of the patent. That is, claim 13 falls entirely within the scope of claim 1 of the patent, or in other words, claim 13 is anticipated by claim 1 of the patent. Claim 1 of the patent limits the coating on the surface of the metal oxide, while claim 13 is generic to the particles but has the same properties as afforded thereby (and such coatings are in dependent claims). For example, the pigment particles defined by claim 1 of the patent are within the scope of the generic claimed pigment particles claimed. Another difference is the claims require at least one polymeric moisturizer, while the patented claims are generic thereto, by optionally having auxiliaries, additives and/or active ingredients, which are defined by the specification to encompass such moisturizers (i.e., claim 7).

Claims 13-18, 21 and 22 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-13 of U.S. Patent No. 6,579,529. Although the conflicting claims are not identical, they are not patentably distinct from each other because claim 13 is generic to all that is recited in claim 1 of the patent. That is, claim 13 falls entirely within the scope of claim 1 of the patent, or in other words, claim 13 is anticipated by claim 1 of the patent. Claim 1 of the patent limits the coating on the surface of the metal oxide, while claim 13 is generic to the particles but has the same properties as afforded thereby (and such coatings are in dependent claims). For example, the pigment particles defined by claim 1 of the patent are within the scope of the generic claimed pigment particles claimed. Another difference is the claims require at least one polymeric moisturizer, while the patented claims are generic thereto, by optionally having auxiliaries, additives and/or active ingredients, which are defined by the specification to encompass such moisturizers.

Claims 13-18, 21 and 22 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-10 of U.S. Patent No. 6,440,399. Although the conflicting claims are not identical, they are not patentably distinct from each other because claim 13 is generic to all that is recited in claim 1 of the patent. That is, claim 13 falls entirely within the scope of claim 1 of the patent, or in other words, claim 13 is anticipated by claim 1 of the patent. Claim 1 of the

Art Unit: 1616

patent limits the coating on the surface of the metal oxide, while claim 13 is generic to the particles but has the same properties as afforded thereby (and such coatings are in dependent claims). For example, the pigment particles defined by claim 1 of the patent are within the scope of the generic claimed pigment particles claimed. The pending claims also recite "Pickering emulsions" in the preamble; however, the specification of the patent defines the emulsions to be Pickering emulsions. Also, since the same components may be present in the claimed and patented emulsions, the term "Pickering" in the preamble of the patent claims does not differentiate. Another difference is the claims require at least one polymeric moisturizer, while the patented claims are generic thereto, by optionally having auxiliaries, additives and/or active ingredients, which are defined by the specification to encompass such moisturizers.

Claims 13-24 rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-9 of U.S. Patent No. 6,410,035. Although the conflicting claims are not identical, they are not patentably distinct from each other because claim 13 is generic to all that is recited in claim 1 of the patent. That is, claim 13 falls entirely within the scope of claim 1 of the patent, or in other words, claim 13 is anticipated by claim 1 of the patent. Claim 1 of the patent limits the coating on the surface of the metal oxide, while claim 13 is generic to the particles but has the same properties as afforded thereby (and such coatings are in dependent claims). For example, the pigment particles defined by claim 1 of the patent are within the scope of the generic claimed pigment particles claimed. Another difference is the claims require at least one polymeric moisturizer, while the patented claims are generic thereto, by optionally having auxiliaries, additives and/or active ingredients, which are defined by the specification to encompass such moisturizers.

Claims 13-18, 21 and 22 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 14-30 of copending Application No. 10/081,547. Although the conflicting claims are not identical, they are not patentably distinct from each other because claim 13 is encompassed by claim 13 of the copending application. For example, the claims require at least one polymeric moisturizer, while the copending claims are generic thereto, by

Art Unit: 1616

optionally having auxiliaries, additives and/or active ingredients, which are defined by the specification to encompass such moisturizers.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.


Conclusion

No claims are allowed at this time.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael G. Hartley whose telephone number is (703) 308-4411. The examiner can normally be reached on M-F, 7:30-5, off alternative Mondays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thurman K. Page can be reached on (703) 308-2927. The fax phone number for the organization where this application or proceeding is assigned is (703) 308-4556.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1235.



Michael G. Hartley
Primary Examiner
Art Unit 1616

MH